UNSPSC 51281612: Elsamicin a or elsamitrucin

This classification denotes a topoisomerase-ii inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C33H35NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTV0FOB6NU, chemically known as 2-amino-2,6-dideoxy-3-o-methyl-d-galactose but generally known as elsamitrucin, which bears US NIH Compound Identifier 5362259. European Medicines Agency schedules Elsamitrucin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06493MIG.

UNSPSC 51281612 Elsamicin a or elsamitrucin, a Commodity code, nominally describes a specific pharmaceutical active ingredient, yet recent state and local procurement activity under this code shows little direct relevance to the code's abstract scope. The most recent opportunities posted involve naloxone and drug deactivation systems (Seminole County, Florida) and antibiotic pharmaceuticals including doxycycline and ciprofloxacin (Illinois Department of Public Health), neither of which aligns with elsamicin or elsamitrucin. State and local buying under this code appears driven by public-health and emergency-response needs rather than the specific pharmaceutical compound the code nominally names. Issuing bodies include county health departments and state public-health agencies procuring through cooperative purchasing vehicles such as MMCAP Infuse and competitive sealed-bid processes.

Geographic activity centers on Florida and Illinois based on recent postings. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Illinois Department of Public Health awarded a piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for pharmaceutical supplies valued at $2,999,999.11 over twelve months plus two one-year renewal options. The mismatch between the code's nominal pharmaceutical scope and the actual procurement activity suggests either miscoding by the issuing bodies or that this code sees limited genuine activity aligned with its stated description.